{"id":39569,"date":"2025-12-08T14:24:35","date_gmt":"2025-12-08T14:24:35","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/gannet-biochem-achieves-science-based-targets-initiative-sbti-validation-for-near-term-climate-commitments\/"},"modified":"2025-12-08T14:24:35","modified_gmt":"2025-12-08T14:24:35","slug":"gannet-biochem-achieves-science-based-targets-initiative-sbti-validation-for-near-term-climate-commitments","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/gannet-biochem-achieves-science-based-targets-initiative-sbti-validation-for-near-term-climate-commitments\/","title":{"rendered":"Gannet BioChem Achieves Science Based Targets initiative (SBTi) Validation for  Near-Term Climate Commitments"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p>Huntsville, AL, Dec.  08, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wbRrSVitv0MFj3q4wz4peWvci96e3ymtVM-k158aflJr18ZrCGpejHYctwFMiOEs3Kaeg_f9QipLgCbA1gNloBXxhSxMLg0DwB6y30Nqp9U=\" rel=\"nofollow\" target=\"_blank\" title=\"Gannet BioChem\">Gannet BioChem<\/a>, a leading specialty chemical Contract Development and Manufacturing Organization (CDMO) backed by Boston-based private equity firm Ampersand Capital Partners, today announced that the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jzBW_ALxqtlk9wXSfHiGaWema2OG_uaVOeNu2K7kLMfkgruMO0Z8FcFHYigAMEFoAOD_TNMEUWLnRkNoiETDpV0es053hl0DguFD-UJZUiAR7jPmBKyNaaZwIsB_cA7sZJuG3t5i80aQVCnS7PKIDQ==\" rel=\"nofollow\" target=\"_blank\" title=\"Science Based Targets initiative (SBTi)\">Science Based Targets initiative (SBTi)<\/a> has validated the company\u2019s near-term greenhouse gas (GHG) emissions reduction targets. This approval marks an important milestone in the company\u2019s sustainability journey and reinforces its commitment to responsible, science-aligned growth.<\/p>\n<p>As part of SBTi\u2019s validation, Gannet BioChem\u2019s approved targets include:<\/p>\n<ul>\n<li style=\"margin-top:0in; margin-bottom:0in;\"><b>Reducing absolute Scope 1 and 2 GHG emissions 63% by 2035<\/b>, using 2020 as the base year<\/li>\n<li style=\"margin-top:0in; margin-bottom:0in;\"><b>Measuring and reducing Scope 3 emissions<\/b> across relevant categories<\/li>\n<\/ul>\n<p>\u201cOur work touches every stage of activated polymer and bioconjugation innovation, from supporting discovery programs to enabling commercial manufacturing,\u201d said <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w1KWBZCNbacS-neGhX32BlmI_3AbjDcDXgTAgyVyoHp-5X7TLbKEneE9Wlb3gxblZa8FBjwk5bGkbxghfxPl0ElkPp3gqgq7LgZtYAsz9CfQQzxfQRJOux7rXJwrvpbj\" rel=\"nofollow\" target=\"_blank\" title=\"Nicholas Shackley\">Nicholas Shackley<\/a>, CEO of Gannet BioChem. \u201cThat reach comes with responsibility. We want to ensure the impact we have on the world is positive, in both a therapeutic and an environmental context. Having our targets validated by SBTi is encouraging and grounding. This confirms we\u2019re on the right path and motivates us to keep pushing forward.\u201d<\/p>\n<p>In recent years, Gannet BioChem has been developing a practical, science-led sustainability framework anchored in transparency and continuous improvement. Efforts underway include increasing energy efficiency at key operational sites, evaluating renewable energy options, strengthening processes for measuring and managing Scope 3 emissions, and building partnerships that prioritize responsible sourcing and lower-impact logistics. These initiatives support a multi-year roadmap to reduce the company\u2019s environmental footprint while meeting the growing needs of the pharmaceutical and life science sectors.<\/p>\n<p><b>About Gannet BioChem<\/b><br \/>With over 30 years of expertise, Gannet BioChem is a leading specialty CDMO specializing in the development, scaling, and manufacturing of polyethylene glycol (PEG) reagents\u2014essential components in advanced biopharmaceutical and therapeutic products. Operating from a state-of-the-art 124,000 sq. ft. FDA-inspected facility in Huntsville, Alabama, Gannet BioChem delivers end-to-end GMP production, supporting clinical and commercial therapeutics. With a highly experienced team, flexible production capabilities, and a commitment to quality, Gannet BioChem provides reliable, innovative solutions to meet the evolving needs of the global biopharmaceutical industry. For additional information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wbRrSVitv0MFj3q4wz4peRFE_N8mXi-KSbwCngbJjjicgvCPIvG-tauBWDtsfCdXmFKpg_-PK7zk0MvILqHXebbaK5ghltxTxPvmd6da-5M=\" rel=\"nofollow\" target=\"_blank\" title=\"GannetBioChem.com\">GannetBioChem.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_oC_cWBVQqB0EjbJ0GWRV1d8y4ae0z45hYsKzyLXlhvfHKzeXJ0Jwy9xF3_4PxMKgMePBTTmRjL1KNhlgqCAUY7FdgxlnjOcAsvdSJwv9_fZ_6kWGDjBWMCaZXsOMi6J\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>.<\/p>\n<p><b>About Ampersand Capital Partners<\/b><br \/>Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with\u00a0$3 billion\u00a0of assets under management, dedicated to growth-oriented investments in the healthcare sector. With hubs in\u00a0Boston,\u00a0Amsterdam, and\u00a0London, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm\u2019s core healthcare sectors. For additional information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WQhWsihJyDV3K9CT9TxfogqjWfd5n7GxnpcDcsw1OCGCnIQctbJAcVKlfUyNicdtDbjCkE4ItcmRIChJz46HjbUH9IFrhYrGScEdcYiwqqvXTNMFsJl_llmeGeql-6TJlZ6fhMl7M84_cuErUhcyDhuOSjOcubi_CW7YWPdO66xmkc5yw9WUodJ2Y6zf2I2sBJUhpgNOU6MbYbMfRQOtmZMKxeCYW6qhrEZpsbxmWIbrVqmh4fwQKC3VLRNppDT3\" rel=\"nofollow\" target=\"_blank\" title=\"www.ampersandcapital.com\">www.ampersandcapital.com<\/a>\u00a0or follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_oC_cWBVQqB0EjbJ0GWRV15MoCsvBdRHr2xqow6KFCWSXRQfC4ZaVEpuGNp-kyZ4Lg8X1CSDO7eXz_Ktwlqkr6TQMdxwfYcNpX35AFj_xk4tiQc7ZJT9VDoUlTBtZmUENgd8hLzkwAlBlb8mW5xpbvmLfv90xzbi6lra0pEdQNK7I1HTVPXg1tC_ZXepPvHpir2WdVOO9Qm7R-GimosIoBPZGrquVr22t8U-VxQ9piFjFcLTsB55z4ifmvWvXM-H\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>.<\/p>\n<pre\/>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Huntsville, AL, Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; Gannet BioChem, a leading specialty chemical Contract Development and Manufacturing Organization (CDMO) backed by Boston-based private equity firm Ampersand Capital Partners, today announced that the Science Based Targets initiative (SBTi) has validated the company\u2019s near-term greenhouse gas (GHG) emissions reduction targets. This approval marks an important milestone [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":39570,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/6acddc86-17ee-4b6b-9bad-29b8c44b6eb6","fifu_image_alt":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-39569","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/39569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/comments?post=39569"}],"version-history":[{"count":0,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/39569\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media\/39570"}],"wp:attachment":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media?parent=39569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/categories?post=39569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/tags?post=39569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}